Safety and efficacy of adjunctive tirofiban and eptifibatide in acute ischemic stroke: A systematic review and meta-analysis
Our meta-analysis suggests that while adjunctive tirofiban or eptifibatide with IVT do not yield benefits in terms of reducing mortality or improving functional independence at 90 days in AIS, emerging evidence from RCTs indicates that tirofiban may offer functional benefits, though this remains uncertain. Importantly, adjunctive therapy did not demonstrate a significant increase in bleeding risk in the analyzed studies. . These findings support the need for further large-scale, high-quality randomized controlled trials to explain the role of tirofiban in the management of AIS.
Authors
- Zain Ul Abideen (ORCID: https://orcid.org/0000-0002-6956-095X)
- Bilawal Nadeem (ORCID: https://orcid.org/0000-0003-1841-8088)
- Muhammad Ehsan (ORCID: https://orcid.org/0009-0002-3233-0971)
- Uzair Jafar (ORCID: https://orcid.org/0000-0003-0737-7444)
- Saad Azam (ORCID: https://orcid.org/0009-0000-1561-5022)
- Raheel Ahmed
- Yahya Abualown
- Usama Ahmed
- Junaid Gulzar
- Ankit Agrawal
- Hameer Ali
- Umair Hayat
- Wajida Perveen
- Rida Shehzad
- Shah e Zaman
Institutions
- Boston Medical Center (US)
- Cleveland Clinic (US)
- King Edward Medical University (PK)
- University of Sargodha (PK)
- University of Karachi (PK)
- CMH Lahore Medical College and Institute of Dentistry (PK)
- Lady Reading Hospital (PK)
- Bahawal Victoria Hospital (PK)
- Chandka Medical College (PK)
- Lung Institute (US)
- Acharya Shri Chander College of Medical Sciences and Hospital (IN)
- Shaikh Zayed Postgraduate Medical Institute (PK)
- Istanbul Medeniyet University (TR)
Publication Details
- Journal
- Journal of Stroke and Cerebrovascular Diseases
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1016/j.jstrokecerebrovasdis.2026.108550
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00